• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Jaguar Health Inc.

    8/13/24 11:02:37 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAGX alert in real time by email
    S-8 1 tm2421436d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 13, 2024

     

      Registration Statement No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    Jaguar Health, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

    46-2956775

    (I.R.S. Employer Identification No.)

     

    200 Pine Street, Suite 400
    San Francisco, California 94104
    (Address of principal executive office) (Zip Code)

     

    New Employee Inducement Award Plan

    (Full title of the plan)

     

    Lisa A. Conte
    Chief Executive Officer and President
    Jaguar Health, Inc.
    200 Pine Street, Suite 400
    San Francisco, California 94104
    (415) 371-8300
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

      Copies to:  
    Donald C. Reinke   Jeffrey G. Aromatorio
    Reed Smith LLP   Reed Smith LLP
    101 Second Street, Suite 1800   Reed Smith Centre, 225 Fifth Avenue
    San Francisco, California 94105   Pittsburgh, PA 15222
    (415) 543-8700   (412) 288-3364

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

     

     

    Large accelerated filer ¨

    Non-accelerated filer x

    Accelerated filer ¨

    Smaller reporting company x

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed by Jaguar Health, Inc. (f/k/a Jaguar Animal Health, Inc.), a Delaware corporation (the “Registrant”), relating to 493,017 shares of its common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible employees of the Registrant under the Registrant’s New Employee Inducement Award Plan (the “Plan”), which Common Stock is in addition to (a) the 37 shares of Common Stock registered on the Registrant’s Form S-8 filed on May 28, 2021 (File No. 333-256629), (b) the 104 shares of Common Stock registered on the Registrant’s Form S-8 filed on April 13, 2022 (File No. 333-264276), and (c) the 8,319 shares of Common Stock registered on the Registrant’s Form S-8 filed on May 15, 2023 (File No. 333-271948). All of the share amounts presented herein reflect the 3-to-1 reverse stock split effective September 8, 2021, the 75-to-1 reverse stock split effective January 23, 2023, and the 60-to-1 reverse stock split effective May 23, 2024.

     

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference

     

    The following documents of Registrant filed with the Securities and Exchange Commission (File No. 001-36714) are incorporated herein by reference:

     

    (a)Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 1, 2024, as amended by the Registrant’s Annual Report on Form 10-K/A filed with the SEC on April 17, 2024;

     

    (b)Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 14, 2024 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 13, 2024;

     

    (c)Registrant’s Current Reports on Form 8-K filed on February 16, 2024, March 1, 2024, March 8, 2024, March 21, 2024, April 9, 2024 (except Item 7.01), May 23, 2024 (except Item 7.01), June 10, 2024, June 21, 2024 (except Item 7.01), June 26, 2024, July 16, 2024, and July 18, 2024; and

     

    (d)The description of our common stock filed as Exhibit 4.26 to Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on April 3, 2020, including any amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

     2 

     

     

    Item 4. Description of Securities

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The following is a list of exhibits filed as part of this Registration Statement, which are incorporated herein:

     

    Exhibit
    No.
       Description
         
    4.1   Specimen Common Stock Certificate of Jaguar Health, Inc. (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2018).
         
    5.1   Opinion of Reed Smith LLP.*
         
    23.1   Consent of RBSM LLP, independent registered public accounting firm.*
         
    23.2   Consent of Reed Smith LLP (included in Exhibit 5.1).*
         
    24.1   Power of Attorney (included on signature page hereto).*
         
    99.1   Jaguar Health, Inc. New Employee Inducement Award Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2020).
         
    99.2   First Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-264276), filed with the Securities and Exchange Commission on April 13, 2022).  
         
    99.3   Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan (incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-271948), filed with the Securities and Exchange Commission on May 15, 2023).  
         
    99.4   Third Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan.*
         
    107   Filing Fee Table.*

     

     

     * Filed herewith

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on this 13th day of August, 2024.

     

      JAGUAR HEALTH, INC.
         
      By: /s/ Lisa A. Conte
      Name: Lisa A. Conte
      Title: Chief Executive Officer and President

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitute and appoint Lisa A. Conte and Carol Lizak, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Lisa A. Conte   Chief Executive Officer, President, and Director   August 13, 2024
    Lisa A. Conte   (Principal Executive Officer)    
             
    /s/ Carol Lizak   Chief Financial Officer and Treasurer (Principal   August 13, 2024
    Carol Lizak   Financial and Accounting Officer)    
             
    /s/ James J. Bochnowski   Chairman of the Board of Directors   August 13, 2024
    James J. Bochnowski        
             
    /s/ Dr. Anula Jayasuriya   Director   August 13, 2024
    Dr. Anula Jayasuriya        
             
    /s/ John Micek III   Director   August 13, 2024
    John Micek III        
             
    /s/ Jonathan B. Siegel   Director   August 13, 2024
     Jonathan B. Siegel        

     

     4 

     

    Get the next $JAGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAGX

    DatePrice TargetRatingAnalyst
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer King Steven R. was granted 11,740 shares, increasing direct ownership by 8,097% to 11,885 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:46 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Conte Lisa A was granted 28,592 shares, increasing direct ownership by 4,293% to 29,258 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:40 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wolin Jonathan S. was granted 11,740 shares, increasing direct ownership by 5,929% to 11,938 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:27 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

    MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

    12/10/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream

    MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayDecember 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

    12/9/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

    MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – TodaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go b

    9/24/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    $JAGX
    SEC Filings

    View All

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    1/23/26 4:15:29 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    1/15/26 5:05:24 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K/A - Jaguar Health, Inc. (0001585608) (Filer)

    1/12/26 1:05:58 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Jaguar Health with a new price target

    Cantor Fitzgerald initiated coverage of Jaguar Health with a rating of Overweight and set a new price target of $5.00

    7/7/21 6:37:12 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Leadership Updates

    Live Leadership Updates

    View All

    Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

    FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar

    9/10/24 10:00:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

    Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and

    4/18/24 8:30:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

    Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr

    4/2/24 8:30:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

    SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

    7/22/24 4:10:52 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jaguar Health Inc. (Amendment)

    SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

    6/10/24 11:26:28 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Jaguar Health Inc.

    SC 13G - Jaguar Health, Inc. (0001585608) (Subject)

    12/29/23 11:09:37 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Financials

    Live finance-specific insights

    View All

    Jaguar Health Reports 2020 Financial Results and Business Updates

    Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.

    3/31/21 4:15:00 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care